Boston Scientific Closes Acquisition of Axonics, Inc.
Boston Scientific (NYSE: BSX) has completed its acquisition of Axonics (Nasdaq: AXNX), a medical technology company specializing in devices for urinary and bowel dysfunction treatment. The acquisition, valued at $3.7 billion in equity value and $3.3 billion in enterprise value, was completed at $71 cash per share. The deal expands Boston Scientific's Urology business into sacral neuromodulation, a high-growth market. The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025, becoming accretive thereafter, though potentially less accretive or more dilutive on a GAAP basis due to amortization and acquisition costs.
Boston Scientific (NYSE: BSX) ha completato l'acquisizione di Axonics (Nasdaq: AXNX), un'azienda tecnologica medica specializzata in dispositivi per il trattamento di disfunzioni urinarie e intestinali. L'acquisizione, valutata 3,7 miliardi di dollari in valore di capitale e 3,3 miliardi di dollari in valore d'impresa, è stata completata a 71 dollari in contante per azione. L'accordo espande il settore Urologia di Boston Scientific nella neuromodulazione sacrale, un mercato in rapida crescita. Si prevede che la transazione non avrà un impatto significativo sugli utili per azione rettificati nel 2024 e 2025, diventando accrescitiva successivamente, sebbene potenzialmente meno accrescitiva o più diluitiva secondo i principi contabili GAAP a causa dell'ammortamento e dei costi di acquisizione.
Boston Scientific (NYSE: BSX) ha completado su adquisición de Axonics (Nasdaq: AXNX), una empresa de tecnología médica especializada en dispositivos para el tratamiento de disfunciones urinarias e intestinales. La adquisición, valorada en $3.7 mil millones en valor de capital y $3.3 mil millones en valor empresarial, se completó a $71 en efectivo por acción. Este acuerdo expande el negocio de Urología de Boston Scientific hacia la neuromodulación sacra, un mercado de alto crecimiento. Se espera que la transacción sea inmaterial para las ganancias ajustadas por acción en 2024 y 2025, volviéndose accretiva posteriormente, aunque potencialmente menos accretiva o más dilutiva en base GAAP debido a la amortización y los costos de adquisición.
보스턴 사이언티픽(Boston Scientific) (NYSE: BSX)가 배뇨 및 장 기능 장애 치료 장치 전문 의료 기술 기업인 아크소닉스(Axonics) (Nasdaq: AXNX)를 인수하였습니다. 이번 인수는 자본 가치 37억 달러, 기업 가치 33억 달러로 평가되며 주당 71달러 현금으로 완료되었습니다. 이 거래는 보스턴 사이언티픽의 비뇨기과 사업을 자극 신경 조절 시장으로 확장시키며, 이는 높은 성장 잠재력을 가진 시장입니다. 이 거래는 2024년과 2025년의 조정된 주당 수익에 큰 영향을 미치지 않을 것으로 예상되며, 이후에는 이익을 증가시킬 것으로 보이나, 감가상각 및 인수 비용으로 인해 GAAP 기준에서는 잠재적으로 덜 증가하거나 더 희석될 수 있습니다.
Boston Scientific (NYSE: BSX) a achevé son acquisition d'Axonics (Nasdaq: AXNX), une entreprise de technologie médicale spécialisée dans les dispositifs de traitement des dysfonctionnements urinaires et intestinaux. L'acquisition, évaluée à 3,7 milliards de dollars en valeur de capitaux propres et 3,3 milliards de dollars en valeur d'entreprise, a été réalisée à 71 dollars en espèces par action. Cette transaction étend les activités d'urologie de Boston Scientific à la neuromodulation sacrale, un marché à forte croissance. On s'attend à ce que la transaction n'ait pas d'impact significatif sur les bénéfices ajustés par action en 2024 et 2025, devenant accretive par la suite, bien qu'elle puisse être moins accretive ou plus dilutive sur une base GAAP en raison de l'amortissement et des coûts d'acquisition.
Boston Scientific (NYSE: BSX) hat die Übernahme von Axonics (Nasdaq: AXNX) abgeschlossen, einem Medizintechnikunternehmen, das auf Geräte zur Behandlung von Blasen- und Darmfunktionsstörungen spezialisiert ist. Die Übernahme, die mit 3,7 Milliarden US-Dollar an Eigenkapitalwert und 3,3 Milliarden US-Dollar an Unternehmenswert bewertet wird, wurde zu 71 US-Dollar in bar pro Aktie abgeschlossen. Die Vereinbarung erweitert das Urologiegeschäft von Boston Scientific in den Bereich der sakralen Neuromodulation, einem wachstumsstarken Markt. Es wird erwartet, dass die Transaktion 2024 und 2025 keinen wesentlichen Einfluss auf die bereinigten Erträge pro Aktie haben wird und danach gewinnbringend wird, jedoch aufgrund von Amortisation und Akquisitionskosten möglicherweise weniger gewinnbringend oder stärker verwässernd nach GAAP-Basis sein könnte.
- Expansion into high-growth sacral neuromodulation market
- Strategic enhancement of Urology business portfolio
- Expected earnings accretion after 2025
- No immediate earnings benefit for 2024-2025
- Potential GAAP earnings dilution due to amortization and acquisition costs
- Significant cash outlay of $3.7 billion for acquisition
Insights
The
The enterprise value of
This acquisition strengthens BSX's competitive position in the $650 million sacral neuromodulation market, which has been growing at double-digit rates. The deal aligns with industry consolidation trends where large medical device companies acquire innovative, specialized players to expand their therapeutic reach.
This acquisition significantly enhances Boston Scientific's urology portfolio by adding Axonics' advanced neuromodulation technology. The deal brings two complementary product lines together - Axonics' r-SNM System and F15 recharge-free SNM system alongside BSX's existing urology solutions. This combination creates a comprehensive treatment pathway for patients with varying degrees of incontinence severity.
The market opportunity is substantial, with over 40 million adults in the US alone suffering from overactive bladder. Axonics' technology has demonstrated superior outcomes and patient satisfaction, which should drive continued market penetration under BSX's larger commercial infrastructure. The integration will likely accelerate international expansion and market access for these innovative therapies.
"Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisition, we're pleased to welcome the Axonics team into Boston Scientific. The addition of the Axonics product portfolio enables us to expand into sacral neuromodulation, a high-growth adjacency for our Urology business, while bringing a comprehensive portfolio of products to patients around the world who are seeking tailored treatment options based on their life stage and incontinence severity."
The purchase price of
Additional information about this transaction is available on the Events and Presentations section of the Boston Scientific investor relations website.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the financial and business impact of the transaction and anticipated benefits of the transaction, our business plans and strategy, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; demographic trends; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the transaction and successfully integrate Axonics' operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the transaction; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACTS:
Nate Gilbraith
Media Relations
+1 (701) 212-9589
nate.gilbraith@bsci.com
Jon Monson
Investor Relations
+1 (508) 683-5450
BSXInvestorRelations@bsci.com
1 Equity value based on total fully diluted share count of approximately 51.7 million shares including management incentives; Enterprise value is equal to Equity value minus net cash and short-term investments of approximately |
View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-closes-acquisition-of-axonics-inc-302307088.html
SOURCE Boston Scientific Corporation
FAQ
How much did Boston Scientific (BSX) pay for Axonics acquisition?
When will the Axonics acquisition be accretive to Boston Scientific (BSX) earnings?
What market segment does the Axonics acquisition add to Boston Scientific (BSX)?
